登录 | 注册    关注公众号  
微信公众号
搜索
 >  Antibody>Bevacizumab >BEB-Y10

Anti-Bevacizumab Antibody (AY10) (MALS verified, recommended for PK/PD)

抗体来源(Source)

Anti-Bevacizumab Antibody (AY10) is a Mouse monoclonal antibody produced from a hybridoma created by fusing SP2/0 myeloma and Mouse B-lymphocytes.

克隆号(Clone)

AY10

种属(Species)

Mouse

亚型(Isotype)

Mouse IgG1/kappa

抗体类型(Antibody Type)

Hybridoma Monoclonal

种属反应性(Reactivity)

Human

免疫原(Immunogen)

Bevacizumab.

特异性(Specificity)

Recognizes Bevacizumab specifically.

应用(Application)

ApplicationRecommended Usage
ELISA10-20000 ng/mL

纯度(Purity)

>95% as determined by SDS-PAGE.

>95% as determined by SEC-MALS.

纯化(Purification)

Protein A purified / Protein G purified

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. 4-8°C for 12 months in lyophilized state;
  2. -70°C for 12 months under sterile conditions after reconstitution.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

电泳(SDS-PAGE)

Bevacizumab SDS-PAGE

Anti-Bevacizumab Antibody (AY10) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

SEC-MALS

Bevacizumab SEC-MALS

The purity of Anti-Bevacizumab Antibody (AY10) (Cat. No. BEB-Y10) is more than 95% and the molecular weight of this protein is around 135-155 kDa verified by SEC-MALS.

Report

 

活性(Bioactivity)-ELISA

Bevacizumab ELISA

Detection of bevacizumab by bridging ELISA in serum. Immobilized Anti-Bevacizumab Antibody (AY10) (Cat. No. BEB-Y10) at 2 μg/mL, add increasing concentrations of bevacizumab (10% human serum) and then add Biotinylated Anti-Bevacizumab Antibody (AY13) (Cat. No. BEB-BY13) at 2 μg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 0.4 μg/mL (QC tested).

Protocol

Bevacizumab ELISA

Immobilized Bevacizumab at 1 μg/mL (100 μL/well) can bind Anti-Bevacizumab Antibody (AY10) (Cat. No. BEB-Y10) with a linear range of 0.39-25 ng/mL.

Protocol

Bevacizumab ELISA

Immobilized Bevacizumab at 2 μg/mL (100 μL/well) can bind pre-mixed Anti-Bevacizumab Antibody (AY10) (Cat. No. BEB-Y10) and Biotinylated Human VEGF165, His,Avitag (Cat. No. VE5-H82Q0) with a inhibition rate of 81%.

Protocol

 
评论(0)
 
ACRO质量管理体系
 
 

背景(Background)

A recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons.

 

前沿进展

Mid-term Combination Immunotherapy and its Effect on the Albumin-Bilirubin Score in Unresectable Hepatocellular Carcinoma
Kuwano, Yada, Tanaka et al
Anticancer Res (2025) 45 (4), 1713-1721
Abstract: Combination immunotherapy has emerged as a standard approach for systemic chemotherapy in unresectable hepatocellular carcinoma (HCC). Preservation of liver function is crucial for prolonging survival during treatment. However, real-world data on liver function dynamics during combination immunotherapy remain limited. This study evaluated the mid-term impact of combination immunotherapy on liver function using the albumin-bilirubin (ALBI) score.Patients receiving durvalumab plus tremelimumab (Dur/Tre group, n=13) or atezolizumab plus bevacizumab (Atez/Bev group, n=35) for at least six months were retrospectively analyzed. ALBI scores were assessed at the start of treatment (SOT), three months, and six months of treatment.In the Dur/Tre group, median (interquartile range) ALBI scores at SOT, three months, and six months of treatment were -2.09 (-2.39 to -1.78), -2.42 (-2.63 to -2.16), and -2.48 (-2.69 to -2.40), respectively, demonstrating a significant improvement at six months compared with SOT (p=0.002). In contrast, the Atez/Bev group exhibited ALBI scores of -2.44 (-2.73 to -2.14), -2.44 (-2.56 to -2.02), and -2.36 (-2.57 to -1.78), indicating significant deterioration at six months of treatment (p=0.010). Among patients with proteinuria, ALBI scores remained unchanged (p=0.171), whereas those without proteinuria experienced significant worsening (p=0.030). In both univariate and multivariate analyses, Dur/Tre treatment [hazard ratio (HR)= 0.022; p=0.005] and objective response rate (HR=0.091; p=0.031) were independently associated with reduced ALBI score deterioration.Dur/Tre therapy may better preserve liver function compared with Atez/Bev therapy in patients with unresectable HCC.Copyright © 2025 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Update on PARP inhibitors for the treatment of ovarian cancer
Liu, Matulonis
Clin Adv Hematol Oncol (2025) 23 (2), 100-110
Abstract: Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors (PARPis) were first granted US Food and Drug Administration (FDA) approval for ovarian cancer. Trials have focused on high-grade serous histology, in which BRCA mutations and homologous recombination deficiency (HRD) are most common. The initial clinical trials of PARPis were performed in patients with heavily pretreated recurrent BRCA-mutated (BRCAm) ovarian cancer. Since then, concerns over possible reductions in overall survival with long-term PARPi treatment in recurrent disease have led to the withdrawal of most FDA approvals in this setting, and the use of PARPis has moved to the maintenance setting in newly diagnosed advanced ovarian cancer, in which trials have demonstrated significant progression-free survival benefits and trends for overall survival benefit with certain PARPis in patients who have BRCA mutations. Additionally, the risks of secondary acute myeloid leukemia and myelodysplastic syndrome are lower in the newly diagnosed setting than in the recurrent setting, potentially because of a predefined duration of PARPi treatment and/or less prior exposure to chemotherapy. Currently, several PARPis are FDA-approved in ovarian cancer: (1) olaparib (BRCAm), niraparib (BRCAm and BRCA wild-type [BRCAwt]), and olaparib/bevacizumab (BRCAm and BRCAwt/HRD) as maintenance therapy after platinum in newly diagnosed advanced disease; and (2) olaparib, niraparib, and rucaparib for recurrent BRCAm platinum-sensitive disease. This review discusses PARPi data in the newly diagnosed and recurrent settings, how current FDA approvals have evolved, and PARPi combination data.
Comparative effectiveness of immunotherapy versus lenvatinib in advanced hepatocellular carcinoma: A real-world analysis using target trial emulation
Ahn, Ng, Yeo et al
Hepatology (2025)
Abstract: Immunotherapy has emerged as an effective treatment for advanced hepatocellular carcinoma (HCC). We aimed to investigate the real-world effectiveness of immunotherapy compared to lenvatinib in HCC.From the TriNetX database, we used a target trial emulation framework and identified HCC patients who received first-line treatment with immunotherapy (atezolizumab/bevacizumab or tremelimumab/durvalumab) or lenvatinib between or between August 2018 and December 2023. Overall survival (OS) was compared using Kaplan-Meier analysis and Cox proportional hazards regression. After propensity score matching, 1203 patients were included in each group. Immunotherapy was associated with improved OS versus lenvatinib (median survival: 545 vs. 425 d; hazard ratio [HR]: 0.86, 95% confidence interval [CI]: 0.76-0.97). Regarding treatment type, atezolizumab plus bevacizumab showed improved survival compared to lenvatinib (n=1070 in each group; HR: 0.87, 95% CI: 0.77-0.99), while the point estimate favored durvalumab plus tremelimumab vs. lenvatinib (HR: 0.81, 95% CI: 0.59-1.12), though this difference was not statistically significant, likely due to small sample size. Regarding etiology, immunotherapy had improved OS compared to lenvatinib in viral hepatitis (n=510 in each group; HR: 0.74, 95% CI: 0.61-0.89) and alcoholic liver disease (n=190 in each group; HR: 0.65, 95% CI: 0.49-0.87), but not in metabolic dysfunction-associated steatotic liver diseases (n=156 in each group; HR: 0.96, 95% CI: 0.70-1.31).In this real-world analysis, immunotherapy was associated with improved OS compared to lenvatinib in advanced HCC, with consistent benefit across most subgroups. These findings support the use of immunotherapy as a first-line treatment for advanced HCC.Copyright © 2025 American Association for the Study of Liver Diseases.
Showing 1-4 of 25316 papers.
Powered by BizGenius
 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定